EPCAM and breast carcinoma: Among the two tumour models of mouse breast cancer used in this study, TUBO, which exhibited higher and uniform EpCAM expression, responded more favourably to the mEp-NIR-PIT + aPD-1 combination therapy compared to the 4T1 model, which exhibited lower and more heterogeneous expression.